FDA-NDA206769
Document details
Summary
Argatroban in 0.9% Sodium Chloride (NDA206769) is a new intravenous formulation of the established direct thrombin inhibitor argatroban, approved via a Type 5 submission by Teva Pharmaceuticals. As anTeva's IV argatroban formulation follows Part B billing pathway.
Affected specialty
Hematology alerts →Source document
http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206769s000lbl.pdfCLV Intelligence summarizes publicly available federal publications. Not affiliated with or endorsed by any government agency.
Related alerts
4Policy FDA-BLA761113 · Hematology
Sarclisa (isatuximab) is an injectable CD38-directed cytolytic antibody approved for multiple myeloma, administered via intravenous injection and billing under Medicare Part B. As a hospital or office
View alertPolicy FDA-BLA761166 · Hematology
Besremi (ropeginterferon alfa-2b) is a subcutaneously administered injectable approved for polycythemia vera, supporting a Part B billing pathway as a physician-administered drug. As an orphan drug in
View alertPolicy FDA-NDA209552 · Hematology
The recent FDA approval of Argatroban as an injectable drug suggests it will likely be assigned a J-code for billing under Medicare Part B. Since it is an anticoagulant, providers may receive pass-thr
View alertPolicy FDA-NDA201743 · Hematology
Argatroban in dextrose is an injectable medication that is likely to receive a J-code assignment for Medicare billing. Since it falls under Part B, billing may involve ASP+6% reimbursement if it meets
View alert